Showing results (111-120 of 196) with videos related to

Sort By:
Pageof 20
Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.
Critical Care Medicine|September 16, 2016
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic LeukemiaJulie C Fitzgerald, Scott L Weiss, Shannon L Maude, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 17, 2020
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 PandemicVeronika Bachanova, Michael R Bishop, Parastoo Dahi, et al.
Nature Medicine|March 15, 2022
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Anqi Dai, Guido Ghilardi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2014
Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioningRan Reshef, Elizabeth O Hexner, Alison W Loren, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2018
Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical TrialRan Reshef, Alex Ganetsky, Edward P Acosta, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2026
A Donor T-Cell Receptor Structural Signature Determines Alloreactive Potential and Predicts Acute Graft-Versus-Host DiseaseXimi K Wang, Ajna Uzuni, Lingting Shi, et al.
Transplantation and Cellular Therapy|May 21, 2023
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T CellsDaniel J Landsburg, Sunita D Nasta, Jakub Svoboda, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
The New England Journal of Medicine|December 12, 2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasStephen J Schuster, Jakub Svoboda, Elise A Chong, et al.
Pageof 20